Duchenne and Becker muscular dystrophies are caused by genetic lesions of the dystrophin gene. These mutations result in the production of an abnormal protein or its absence. The long term goal of our research is to fully characterize the function of dystrophin to facilitate early detection, treatment and perhaps prevention of muscular dystrophy. During the last three years, we have identified and characterized a protein module, the WW domain, which binds proline rich ligands. The WW domain is present within the carboxyterminal region of dystrophin. Dystrophin interacts with several proteins including B-dystroglycan, which spans the membrane and communicates with the extracellular matrix. The overall hypothesis to be evaluated is that the WW domain, EF hands and the ZZ domain of dystrophin mediate interaction with B-dystroglycan in vivo, and that without this interaction, a partial or complete dystrophic phenotype results at the level of organism.
Our specific aims are: 1. To characterize the specificity of the interaction between the WW domain of dystrophin and the proline rich core of B-dystroglycan using site directed mutagenesis, phage displayed peptide repertoires, the SPOT technique of peptide synthesis, and immunoprecipitation. 2. To elucidate the role of the cysteine rich region of dystrophin in modulating the interaction between the WW domain, EF hands plus the Z domain of dystrophin and B-dystroglycan by mutational analysis and x-ray crystallography. 3. To provide evidence of the biological role of modular protein domains of dystrophin (the WW domain, EF hands, the Z domain) by showing that dystrophin transgenes in which any of the four domains alone or in combination with other modules is point mutated can only partially complement the mdx phenotype (muscular dystrophy in mice), in contrast to the control, a wild type transgene, which fully complements the mdx phenotype. These studies will provide insight into molecular function of dystrophin and could point towards potential therapies for Duchenne and Becker muscular dystrophies.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Research Project (R01)
Project #
5R01AR045626-02
Application #
6375167
Study Section
Cell Development and Function Integrated Review Group (CDF)
Program Officer
Lymn, Richard W
Project Start
2000-08-15
Project End
2003-07-31
Budget Start
2001-08-01
Budget End
2002-07-31
Support Year
2
Fiscal Year
2001
Total Cost
$164,415
Indirect Cost
Name
Mount Sinai School of Medicine
Department
Biochemistry
Type
Schools of Medicine
DUNS #
114400633
City
New York
State
NY
Country
United States
Zip Code
10029
Clump, David A; Qazi, Ihtishaam H; Sudol, Marius et al. (2005) c-Yes response to growth factor activation. Growth Factors 23:263-72
Hu, Hai; Columbus, John; Zhang, Yi et al. (2004) A map of WW domain family interactions. Proteomics 4:643-55
Komuro, Akihiko; Nagai, Makoto; Navin, Nicholas E et al. (2003) WW domain-containing protein YAP associates with ErbB-4 and acts as a co-transcriptional activator for the carboxyl-terminal fragment of ErbB-4 that translocates to the nucleus. J Biol Chem 278:33334-41
Strano, S; Munarriz, E; Rossi, M et al. (2001) Physical interaction with Yes-associated protein enhances p73 transcriptional activity. J Biol Chem 276:15164-73
Wu, X; Chang, A; Sudol, M et al. (2001) Genetic interactions between the ESS1 prolyl-isomerase and the RSP5 ubiquitin ligase reveal opposing effects on RNA polymerase II function. Curr Genet 40:234-42
Espanel, X; Sudol, M (2001) Yes-associated protein and p53-binding protein-2 interact through their WW and SH3 domains. J Biol Chem 276:14514-23
Sudol, M; Sliwa, K; Russo, T (2001) Functions of WW domains in the nucleus. FEBS Lett 490:190-5